Summary
While the introduction of the 9-valent HPV vaccine offers additional protection against strains known to produce cancer, the low level of HPV vaccine uptake throughout the United States lessens the potential benefits of the vaccine on an individual and societal basis. New initiatives, at the local as well as the state and national levels, are needed to inform the public of the efficacy and safety of the vaccine.